同仁堂科技(01666.HK)2024年度業績：營收增長7.18%至72.60億元，穩步推進大品種戰略
格隆匯3月28日丨同仁堂科技(01666.HK)公佈年度業績，2024年，集團繼續深入貫徹「十四五」規劃，持續將工作重心聚焦於「同仁堂服務年」主線，並堅定不移地實施「大品種」核心戰略。截至2024年12月31日止年度，集團收入爲人民幣72.60億元，較上年同期增長7.18%；實現淨利潤爲人民幣8.87億元，歸屬於公司所有者淨利潤爲人民幣5.22億元，每股收益爲人民幣0.41元，每股股息爲人民幣0.18元。
2024年，集團銷售額超過人民幣500萬元的產品五十六個，其中，銷售額超過億元的產品九個。主導產品中，六味地黃丸系列銷售額較上年同期增長10.71%、生脈飲口服液系列銷售額較上年同期增長14.85%、感冒清熱顆粒系列銷售額較上年同期增長17.14%，金匱腎氣丸系列銷售額較上年同期增長3.45%，加味逍遙系列銷售額較上年同期增長5.02%。
報告期內，公司與北京中醫藥大學合作的創新藥芪參顆粒順利獲得臨牀試驗批準通知書。同時，集團持續在經典名方開發方面發力，繼續推動苓桂術甘湯、芍藥甘草湯等多個品種的研發工作。現有產品二次科研方面，針對京制牛黃解毒片、附子理中丸等多個產品開展藥理機制研究，明確藥品有效成分，深入挖掘相關產品的價值特點。此外，集團針對生脈飲口服液、杞菊地黃丸等產品開展臨牀研究，積累循證醫學數據，爲產品的臨牀應用提供堅實的科學依據，進一步提升產品的市場競爭力與臨牀認可度。
2025年，是集團全面踐行「十四五」規劃的收官之年，集團將繼續緊密圍繞「十四五」規劃及大品種戰略的方向，科學謀劃並穩步推進一系列關鍵舉措。集團將持續優化構建戰略管理體系，深入推進營銷體系改革，構建線上線下融合、多元化、精準化的營銷模式，提升產品的市場影響力與佔有率。集團將通過踐行一系列舉措，不斷催生並提升新質生產力，爲即將開啓的「十五五」時期築牢發展根基。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
